Eton Pharmaceuticals (ETON) revenue breakdown
By product, Product Sales and Royalties is the largest at 96% of fiscal 2025 revenue, growing 178% a year over 5 years.
Revenue by product
Fiscal years, as Eton Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $80M.
| Products | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Product Sales and Royalties | $459,000 | $3M | $11M | $26M | $39M | $77M | 96% |
| License | $500,000 | $19M | $10M | $6M | $500,000 | $3M | 4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ETON.
Open ETON in InvestinglyQuestions
Where does Eton Pharmaceuticals make its money?
In fiscal 2025, by product: Product Sales and Royalties $77M, License $3M.
From Eton Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.